PRISMA study: Personalised RISk-based MAmmascreening

PRISMA study: Personalised RISk-based MAmmascreening - PRISMA study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44455

Enrollment

90000

Registered

2014-06-25

Start date

2014-09-15

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Women invited for breast cancer screening - Able to communicate in Dutch - Able to read and understand the participant information and informed consent form

Exclusion criteria

Exclusion criteria: - Women who cannot make the decision to participate by themselves (mentally ill or mentally handicapped) - Not able to fill out a web-based questionnaire

Design outcomes

Primary

Measure	Time frame
Since the purpose of this study is developing a risk prediction model for breast cancer, there is no primary study parameter as such. Measures to compare the current risk prediction models and the newly developed models will be the Area under the Receiver Operator Characteristic curve (AUCROC), decision analytic measures, like the Net Reclassification Improvement (NRI), and the Integrated Discrimination Improvement (IDI).	—

Measure

Time frame

Since the purpose of this study is developing a risk prediction model for breast cancer, there is no primary study parameter as such. Measures to compare the current risk prediction models and the newly developed models will be the Area under the Receiver Operator Characteristic curve (AUCROC), decision analytic measures, like the Net Reclassification Improvement (NRI), and the Integrated Discrimination Improvement (IDI).

—

Secondary

Measure	Time frame
We will use the well-establised MISCAN model to assess the cost-effectiveness of the most promising risk-based screening scenarios.	—

Countries

Netherlands

Outcome results